Summary:
Psychiatric Care and Research Center is conducting a multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Rapastinel as adjunctive therapy in treating subjects with Major Depression. This will be a 3 week study in subjects who have a partial response to their antidepressant. This is a new antidepressant with a novel mechanism of action and will be given intravenously.
Qualified Participants Must:
• Be between 18 and 65 years of age
•
Have a current episode of depression lasting at least 8 weeks but not more than 18 months
•
Have no more than a partial response to their ongoing antidepressant treatment
•
Not have received a mood stabilizer within the past year or antipsychotic within the current episode
•
Not have Schizophrenia, Bipolar Disorder, or Substance Abuse within the last 6 months
Qualified Participants May Receive:
Compensation for time and travel may be possible.
Complete medical examination.